Clinical outcomes of stereotactic radiosurgery in the treatment of patients with metastatic brain tumors
- PMID: 21704935
- DOI: 10.1016/j.wneu.2010.12.006
Clinical outcomes of stereotactic radiosurgery in the treatment of patients with metastatic brain tumors
Abstract
Background: Stereotactic radiosurgery (SRS) is a form of radiation therapy that delivers a focused, highly conformal dose of radiation to a single volume, while minimizing damage to the adjacent nervous tissue. The efficacy of SRS has been examined in the treatment of patients diagnosed with brain metastases due to the fact that it is capable of targeting any region in the brain and can irradiate multiple tumors in the same treatment setting in a noninvasive fashion.
Methods: Modern literature was reviewed for studies on SRS in the treatment of patients with brain metastases.
Results: After assessing patient age, Karnofsky Performance Score (KPS), control of primary cancer, presence of extracranial metastases, number of brain metastases, location of brain metastases, and size of brain metastases, SRS offers suitable patients a viable, less invasive treatment option. In patients with 1 to 4 brain metastases who have a KPS ≥70, the addition of SRS to whole-brain radiation therapy (WBRT) produces increased levels of survival and local tumor control when compared with patients treated with WBRT alone. The available evidence suggests that specific patients treated with SRS alone exhibit superior levels of survival and tumor control when compared with patients treated with WBRT alone. Further evidence in the form of a randomized trial is needed to confirm this observation. Questions remain regarding survival and tumor control in patient groups treated with SRS with or without WBRT. Recently published randomized evidence reported a survival advantage in patients treated with SRS alone. These data differ from other previously published randomized evidence, as well as several prospective and retrospective studies, which reported nonsignificant survival differences. Contrasting evidence also exists pertaining to local and distant tumor control, which warrants further investigation into this matter. The available evidence suggests that in patients with 1 to 2 brain metastases, both SRS alone and SRS with WBRT offer equivalent levels of survival when compared with patients treated with surgery with WBRT. Research has been conducted that reports a survival advantage in patients with 1 to 3 brain metastases that were treated with SRS with WBRT.
Conclusions: SRS can be an advantageous course of treatment in specific patient groups when utilized alone, after surgery, with WBRT, or in combination with either or both of the treatment modalities. Although treatment approaches have been refined, many questions remain unanswered and further clinical evidence is needed to guide physicians in their future treatment decisions regarding treating patients in specific clinical scenarios.
Copyright © 2011 Elsevier Inc. All rights reserved.
Similar articles
-
Whole brain radiation therapy (WBRT) alone versus WBRT and radiosurgery for the treatment of brain metastases.Cochrane Database Syst Rev. 2017 Sep 25;9(9):CD006121. doi: 10.1002/14651858.CD006121.pub4. Cochrane Database Syst Rev. 2017. PMID: 28945270 Free PMC article. Review.
-
Application of recursive partitioning analysis and evaluation of the use of whole brain radiation among patients treated with stereotactic radiosurgery for newly diagnosed brain metastases.Int J Radiat Oncol Biol Phys. 2000 Jul 1;47(4):993-9. doi: 10.1016/s0360-3016(00)00527-7. Int J Radiat Oncol Biol Phys. 2000. PMID: 10863070
-
The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline.J Neurooncol. 2010 Jan;96(1):45-68. doi: 10.1007/s11060-009-0073-4. Epub 2009 Dec 4. J Neurooncol. 2010. PMID: 19960227 Free PMC article. Review.
-
Whole brain radiation therapy (WBRT) alone versus WBRT and radiosurgery for the treatment of brain metastases.Cochrane Database Syst Rev. 2012 Sep 12;2012(9):CD006121. doi: 10.1002/14651858.CD006121.pub3. Cochrane Database Syst Rev. 2012. Update in: Cochrane Database Syst Rev. 2017 Sep 25;9:CD006121. doi: 10.1002/14651858.CD006121.pub4. PMID: 22972090 Free PMC article. Updated. Review.
-
Cost-effectiveness of stereotactic radiosurgery with and without whole-brain radiotherapy for the treatment of newly diagnosed brain metastases.J Neurosurg. 2014 Dec;121 Suppl:84-90. doi: 10.3171/2014.7.GKS14972. J Neurosurg. 2014. PMID: 25434941
Cited by
-
Prognostic factors associated with the transition in treatment methods for brain metastases from colorectal cancer.Int J Clin Oncol. 2023 Aug;28(8):1043-1053. doi: 10.1007/s10147-023-02352-8. Epub 2023 May 19. Int J Clin Oncol. 2023. PMID: 37208499 Free PMC article.
-
Single Solitary Fibrous Tumor Brain Metastasis in a Patient with Simultaneous Adenocarcinoma of the Lung: Case Report and Review of the Literature.Case Rep Med. 2020 Apr 7;2020:3938270. doi: 10.1155/2020/3938270. eCollection 2020. Case Rep Med. 2020. PMID: 32318112 Free PMC article.
-
Do we have a "game changer" in treating patients with brain metastasis from renal cell carcinoma?Ann Transl Med. 2019 Dec;7(Suppl 8):S360. doi: 10.21037/atm.2019.09.50. Ann Transl Med. 2019. PMID: 32016078 Free PMC article. No abstract available.
-
Health-related quality of life of patients with brain metastases selected for stereotactic radiosurgery.J Neurooncol. 2019 Jul;143(3):537-546. doi: 10.1007/s11060-019-03186-z. Epub 2019 May 9. J Neurooncol. 2019. PMID: 31073966 Free PMC article.
-
In silico assessment of the dosimetric quality of a novel, automated radiation treatment planning strategy for linac-based radiosurgery of multiple brain metastases and a comparison with robotic methods.Radiat Oncol. 2018 Mar 15;13(1):41. doi: 10.1186/s13014-018-0997-y. Radiat Oncol. 2018. PMID: 29544504 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical